{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T21:55:06Z","timestamp":1787090106684,"version":"build-2736575974"},"reference-count":76,"publisher":"Walter de Gruyter GmbH","issue":"1","funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical medicine, Development of special funding support","doi-asserted-by":"publisher","award":["XMLX201710"],"award-info":[{"award-number":["XMLX201710"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"publisher","award":["Z161100000516143"],"award-info":[{"award-number":["Z161100000516143"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Doctors and patients fear the risk of breast cancer when using hormone replacement therapy (HRT). This review focuses on the choice of progestogen for HRT in menopausal. The Women\u2019s Health Initiative (WHI) has been the only large double-blind placebo-controlled study testing the risk of breast cancer (BC) using HRT. No increased risk using estrogen (E)-only was seen, there was a significant decrease in mortality due to BC after the use of HRT which persisted during the recent 18-year follow-up of the WHI. In contrast in the combined arm the risk increased. In about 20 observational studies using mostly medroxyprogesterone acetate (MPA) or estradiol-norethisterone acetate (NETA) an increased BC-risk was observed comparable with the WHI. Only for natural progestogen, progesterone and for dydrogesterone (retro-isomer of progesterone) was no increased risk seen for up to 5\u20138 years, when compared directly with other progestogens, but for longer treatment an increased risk cannot be excluded. In contrast, the mortality due to BC after use of E-only and combined HRT decreased in about a dozen observational studies, and was very recently confirmed in a Finnish study evaluating 490,000 women using estradiol (E2) plus different progestogens. There have been already more than 70 studies evaluating the risk of BC during HRT, and still there are many open questions. Therefore, this review covers our own and other experimental research which could answer important questions. Experimental research has demonstrated that certain synthetic progestogens, but not progesterone and to some extent also not dydrogesterone, can accelerate the proliferation of breast cancer cells in vitro and in animal studies via special cell membrane components which we recently also detected in patients with BC, and we found differences comparing all available synthetic progestogens. Derived from these mechanisms future research may provide screening for patients at risk and predict the prognosis of possible BC.<\/jats:p>","DOI":"10.1515\/hmbci-2018-0019","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T04:14:10Z","timestamp":1534565650000},"source":"Crossref","is-referenced-by-count":10,"title":["The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue"],"prefix":"10.1515","volume":"37","author":[{"given":"Xiangyan","family":"Ruan","sequence":"first","affiliation":[{"name":"Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China"},{"name":"University Hospitals of T\u00fcbingen , Department of Women\u2019s Health , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred O.","family":"Mueck","sequence":"additional","affiliation":[{"name":"Beijing Obstetrics and Gynecology Hospital , Capital Medical University , Beijing , China"},{"name":"University Hospitals of T\u00fcbingen , Department of Women\u2019s Health , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"key":"2025121207110104152_j_hmbci-2018-0019_ref_001_w2aab3b7b2b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women\u2019s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321\u201333.","DOI":"10.1001\/jama.288.3.321"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_002_w2aab3b7b2b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women\u2019s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial. J Am Med Assoc. 2004;291:701\u201312.","DOI":"10.1001\/jama.291.14.1701"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_003_w2aab3b7b2b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Baber RJ, Panay N, Fenton A, (on behalf of the IMS Writing Group). 2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy. Climacteric. 2016;19:109\u201350.","DOI":"10.3109\/13697137.2015.1129166"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_004_w2aab3b7b2b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Neves-E-Castro M, Birkhauser M, Samsioe G, Lambrinoudaki I, Palacios S, Borrego RS, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81:88\u201392.","DOI":"10.1016\/j.maturitas.2015.02.003"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_005_w2aab3b7b2b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19:257\u201371.","DOI":"10.1097\/gme.0b013e31824b970a"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_006_w2aab3b7b2b1b6b1ab2b1b6Aa","unstructured":"German S3 Guideline on HRT (Ortmann O, on behalf of 19 German Societies). Hormonal therapy in peri- and postmenopause. Short version of interdisciplinary S3 guideline. Frauenarzt. 2009;10:840\u201351."},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_007_w2aab3b7b2b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(Suppl. 1):s1\u201366.","DOI":"10.1210\/jc.2009-2509"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_008_w2aab3b7b2b1b6b1ab2b1b8Aa","unstructured":"NICE Guidelines. Menopause: diagnosis and management. Available from: https:\/\/www.nice.org.uk\/guidance\/ng23\/resources\/menopause-diagnosis-and-managment-1837330217413. Accessed: 12 Dec 2015."},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_009_w2aab3b7b2b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"de Villiers T, Hall JE, Pinkerton J, Cerdas Perez S, Reese M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19:313\u20135.","DOI":"10.1080\/13697137.2016.1196047"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_010_w2aab3b7b2b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. J Am Med Assoc. 2017;318:2224\u201333.","DOI":"10.1001\/jama.2017.18261"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_011_w2aab3b7b2b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. J Am Med Assoc. 2006;295:1647\u201357.","DOI":"10.1001\/jama.295.14.1647"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_012_w2aab3b7b2b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Scarabin PY, Oger E, Plu-Bureau G (for the ESTHER Study Group). Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428\u201332.","DOI":"10.1016\/S0140-6736(03)14066-4"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_013_w2aab3b7b2b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Canonico M, Plu-Bureau G, Lowe GD, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: a systematic review and meta-analysis. Br Med J. 2008;336:1227\u201331.","DOI":"10.1136\/bmj.39555.441944.BE"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_014_w2aab3b7b2b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Renoux C, Dell-Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thrombosis Haemostasis. 2010;8:979\u201386.","DOI":"10.1111\/j.1538-7836.2010.03839.x"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_015_w2aab3b7b2b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Simon JA, Lalibert\u00e9 F, Duh MS, Pilon D, Kahler KH, Nyirady J, et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016;23:600\u201310.","DOI":"10.1097\/GME.0000000000000590"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_016_w2aab3b7b2b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Renoux C, Dell\u2019Aniello S, Garbe D, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Br Med J. 2010;340:c2519.","DOI":"10.1136\/bmj.c2519"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_017_w2aab3b7b2b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric. 2010;13:429\u201332.","DOI":"10.3109\/13697137.2010.507111"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_018_w2aab3b7b2b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, et al. Postmenopausal hormone therapy and risk of stroke. Impact of the route of estrogen administration and type of progestogen. Stroke. 2016;47:1734\u201341.","DOI":"10.1161\/STROKEAHA.116.013052"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_019_w2aab3b7b2b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Canonico M, Scarabin P-Y. Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003? Menopause. 2016;23:587\u20138.","DOI":"10.1097\/GME.0000000000000665"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_020_w2aab3b7b2b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012;15(Suppl 1):11\u20137.","DOI":"10.3109\/13697137.2012.669624"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_021_w2aab3b7b2b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Mueck AO, Seeger H. Shapiro S. Risk of breast cancer during hormone replacement therapy: Mechanisms. Horm Mol Biol Clin Invest. 2010;3:329\u201339.","DOI":"10.1515\/HMBCI.2010.037"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_022_w2aab3b7b2b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Mueck AO, Ruan X. Benefits and risks during HRT \u2013 main safety issue breast cancer. Horm Mol Biol Clin Invest. 2011;5:105\u201316.","DOI":"10.1515\/HMBCI.2011.014"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_023_w2aab3b7b2b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal Hormone Therapy and long-term all-cause and cause-specific mortality: the women\u2019s health initiative randomized trials. J Am Med Assoc. 2017;318:927\u201338.","DOI":"10.1001\/jama.2017.11217"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_024_w2aab3b7b2b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Manson JE, Kaunitz AM. Menopause management \u2013 Getting clinical care back on track. N Engl J Med. 2016;374:803\u20136.","DOI":"10.1056\/NEJMp1514242"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_025_w2aab3b7b2b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017;20:91\u20136.","DOI":"10.1080\/13697137.2017.1280251"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_026_w2aab3b7b2b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol. 1994;8:1347\u201360.","DOI":"10.1210\/mend.8.10.7854352"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_027_w2aab3b7b2b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 2000;289:1751\u20134.","DOI":"10.1126\/science.289.5485.1751"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_028_w2aab3b7b2b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA. 2003;100:9744\u20139.","DOI":"10.1073\/pnas.1732707100"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_029_w2aab3b7b2b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999;13:829\u201336.","DOI":"10.1210\/mend.13.6.0290"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_030_w2aab3b7b2b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Bergink EW, van Meel F, Turpijn EW, van der Vies J. Binding of progestagens to receptor proteins in MCF-7 cells. J Steroid Biochem. 1983;19:1563\u201370.","DOI":"10.1016\/0022-4731(83)90371-0"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_031_w2aab3b7b2b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Kontula K, Janne O, Vihko R, de Jager E, de Visser J, Zeelen F. Progesteronebinding proteins: In vitro binding and biological activity of different steroidal ligands. Acta Endocrinol. 1975;78:574\u201392.","DOI":"10.1530\/acta.0.0780574"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_032_w2aab3b7b2b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Ghatge R, Jacobsen B, Schittone S, Horwitz K. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res. 2005;7:R1036\u201350.","DOI":"10.1186\/bcr1340"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_033_w2aab3b7b2b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, et al. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005;97:328\u201341.","DOI":"10.1016\/j.jsbmb.2005.06.032"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_034_w2aab3b7b2b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Moore NL, Hickey TE, Butler LM, Tilley WD. Multiple nuclear receptor signalling pathways mediate the actions of synthetic progestins in target cells. Mol Cell Endocrinol. 2012;397:60\u201370.","DOI":"10.1016\/j.mce.2011.09.019"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_035_w2aab3b7b2b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol. 2005;19:574\u201387.","DOI":"10.1210\/me.2004-0287"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_036_w2aab3b7b2b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev. 1980;60:1049\u2013106.","DOI":"10.1152\/physrev.1980.60.4.1049"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_037_w2aab3b7b2b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11:266\u2013301.","DOI":"10.1210\/edrv-11-2-266"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_038_w2aab3b7b2b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"McManus MJ, Welsch CW. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer. 1984;54:1920\u20137.","DOI":"10.1002\/1097-0142(19841101)54:9<1920::AID-CNCR2820540924>3.0.CO;2-F"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_039_w2aab3b7b2b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology. 1995;136:164\u201371.","DOI":"10.1210\/endo.136.1.7828527"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_040_w2aab3b7b2b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer EA, Seeger H, Kr\u00e4mer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod. 2006;27:39\u2013141.","DOI":"10.1016\/j.ejogrb.2005.12.004"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_041_w2aab3b7b2b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"van der Burg B, Kalkhoven E, Isbr\u00fccker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42:457\u201365.","DOI":"10.1016\/0960-0760(92)90257-J"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_042_w2aab3b7b2b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: 1.MCF-7 cell lines. J Steroid Biochem Mol Biol. 1995;55:423\u201337.","DOI":"10.1016\/0960-0760(95)00215-4"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_043_w2aab3b7b2b1b6b1ab2b1c43Aa","unstructured":"Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res. 1995;15:2551\u20136."},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_044_w2aab3b7b2b1b6b1ab2b1c44Aa","unstructured":"Lippert C, Seeger H, Wallwiener D, Mueck AO. The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol\/progestin treatment. Eur J Gynaecol Oncol. 2001;22:331\u20135."},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_045_w2aab3b7b2b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000;11:99\u2013110.","DOI":"10.1016\/S0960-0760(00)00132-1"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_046_w2aab3b7b2b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Santen RJ, Xinde Song R, McPherson R, Kumar R, Adam L, Jeng MH, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80:239\u201356.","DOI":"10.1016\/S0960-0760(01)00189-3"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_047_w2aab3b7b2b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Fu XD, Giretti MS, Goglia L, Flamini MI, Sanchez AM, Baldacci C, et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer. 2008;8:166\u201371.","DOI":"10.1186\/1471-2407-8-166"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_048_w2aab3b7b2b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"Losel RM, Besong D, Peluso JJ, Wehling M. Progesterone receptor membrane component 1 \u2013 many tasks for a versatile protein. Steroids 2008;73:929\u201334.","DOI":"10.1016\/j.steroids.2007.12.017"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_049_w2aab3b7b2b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol. 2007;105:16\u201336.","DOI":"10.1016\/j.jsbmb.2007.02.002"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_050_w2aab3b7b2b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein\/human progesterone receptor) in tumors. Tumour Biol. 2005;26:142\u20136.","DOI":"10.1159\/000086485"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_051_w2aab3b7b2b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Neubauer H, Ma Q, Zhou J, Yu Q, Ruan X, Seeger H, et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2013;16:509\u201313.","DOI":"10.3109\/13697137.2013.800038"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_052_w2aab3b7b2b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Ruan X, Zhang Y, Mueck AO, Willibald M, Seeger H, Fehm T, et al. Increased expression of progesterone membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and \u2013 negative breast cancer. Menopause. 2017;24:203\u20139.","DOI":"10.1097\/GME.0000000000000739"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_053_w2aab3b7b2b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Neubauer H, Adam G, Fehm T, Seeger H, Neubauer H, Solomayer E, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF gene expression in human breast cancer cells. Climacteric. 2009;12:230\u20139.","DOI":"10.1080\/13697130802635637"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_054_w2aab3b7b2b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"Neubauer H, Yang Y, Seeger H, Fehm T, Tong X, Cahill MA, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause. 2011;18:845\u201350.","DOI":"10.1097\/gme.0b013e31820e5ac5"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_055_w2aab3b7b2b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"Ruan X, Neubauer H, Yang Y, Schneck E, Schultz S, Fehm T, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric. 2012;15:467\u201372.","DOI":"10.3109\/13697137.2011.648232"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_056_w2aab3b7b2b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Ruan X, Neubauer H, Schneck H, Schultz S, Fehm T, CaHill MA, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol. 2012;28:863\u20136.","DOI":"10.3109\/09513590.2012.671396"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_057_w2aab3b7b2b1b6b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"Schneck H, Ruan X, Seeger H, Cahill MA, Fehm T, Neubauer H, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol. 2013;29:160\u20133.","DOI":"10.3109\/09513590.2012.730572"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_058_w2aab3b7b2b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause. 2013;20:504\u201310.","DOI":"10.1097\/gme.0b013e3182755c97"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_059_w2aab3b7b2b1b6b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"Zhou J, Yu Q, Chen R, Seeger H, Fehm T, Cahill MA, et al. Medroxyprogesterone acetate- driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. Maturitas. 2013;76:129\u201333.","DOI":"10.1016\/j.maturitas.2013.06.013"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_060_w2aab3b7b2b1b6b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"Zhang Y, Ruan X, Willibald M, Seeger H, Fehm T, Neubauer H, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer? Gynecol Endocrinol. 2016;32:58\u201360.","DOI":"10.3109\/09513590.2015.1078303"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_061_w2aab3b7b2b1b6b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"Zhao Y, Ruan X, Wanga H, Lia X, Gua M, Wang L, Li Y, et al. The presence of membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model. Maturitas. 2017;102:26\u201333.","DOI":"10.1016\/j.maturitas.2017.05.007"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_062_w2aab3b7b2b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"Stanczyk FZ. Editorial. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women\u2019s Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause. 2011;18:833\u20134.","DOI":"10.1097\/gme.0b013e3182260321"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_063_w2aab3b7b2b1b6b1ab2b1c63Aa","doi-asserted-by":"crossref","unstructured":"Willibald M, Bayer G, Stahlhut V, Poschmann G, St\u00fchler K, Gierke B, et al. Progesterone Receptor Membrane Component 1 is Phosphorylated upon Progestin Treatment in Breast Cancer Cells. Oncotarget (advanced publications). Available from: www.impactjournals.com\/oncotarget\/. Accepted: 28 Jun 2017.","DOI":"10.18632\/oncotarget.19819"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_064_w2aab3b7b2b1b6b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"Seeger H, Ruan X, Neubauer H, Brucker S, Mueck A. Membrane-initiated effects of Serelys\u00ae on proliferation and apoptosis of human breast cancer cells. Gynecol Endocrinol. 2017; epub ahead (Nov 5, 2017).","DOI":"10.1080\/09513590.2017.1407751"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_065_w2aab3b7b2b1b6b1ab2b1c65Aa","doi-asserted-by":"crossref","unstructured":"Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women\u2019s Health Initiative Randomized Trial. J Am Med Assoc. 2003;289:3243\u201353.","DOI":"10.1001\/jama.289.24.3243"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_066_w2aab3b7b2b1b6b1ab2b1c66Aa","doi-asserted-by":"crossref","unstructured":"Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer. 2016;115:607\u201315.","DOI":"10.1038\/bjc.2016.231"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_067_w2aab3b7b2b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"Asi N, Mohammed K, Haydour Q, Gionfriddo MR, Vargas OL, Prokop LJ, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Systematic Rev. 2016;5:121\u20139.","DOI":"10.1186\/s13643-016-0294-5"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_068_w2aab3b7b2b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"de Ligni\u00e8res B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002;5:332\u201340.","DOI":"10.1080\/cmt.5.4.332.340"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_069_w2aab3b7b2b1b6b1ab2b1c69Aa","doi-asserted-by":"crossref","unstructured":"Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103\u201311.","DOI":"10.1007\/s10549-007-9523-x"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_070_w2aab3b7b2b1b6b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;11:1\u20139.","DOI":"10.1371\/journal.pone.0078016"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_071_w2aab3b7b2b1b6b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65\u201373.","DOI":"10.1097\/AOG.0b013e31818e8cd6"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_072_w2aab3b7b2b1b6b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol\/dydrogesterone or other HRT preparations. Climacteric. 2009;12:514\u201324.","DOI":"10.3109\/13697130903075352"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_073_w2aab3b7b2b1b6b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. 2018;21:111\u201322.","DOI":"10.1080\/13697137.2017.1421925"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_074_w2aab3b7b2b1b6b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128:144\u201356.","DOI":"10.1002\/ijc.25314"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_075_w2aab3b7b2b1b6b1ab2b1c75Aa","doi-asserted-by":"crossref","unstructured":"Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol. 2002;186:325\u201334.","DOI":"10.1067\/mob.2002.121077"},{"key":"2025121207110104152_j_hmbci-2018-0019_ref_076_w2aab3b7b2b1b6b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause. 2016;23:1199\u2013203.","DOI":"10.1097\/GME.0000000000000698"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2019.37.issue-1\/hmbci-2018-0019\/hmbci-2018-0019.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0019\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:54:59Z","timestamp":1765526099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2018-0019\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,8,18]]},"published-print":{"date-parts":[[2019,1,28]]}},"alternative-id":["10.1515\/hmbci-2018-0019"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2018-0019","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"article-number":"20180019"}}